contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Medicover är verksamt inom hälso- och sjukvårdsbranschen. Bolaget är ett internationellt vård- och diagnostikbolag och fokuserar på tillhandahållande av medicinska tjänster och laboratorieanalyser. Bolagets tjänster riktar sig till privatpersoner och företag som behöver snabb och tillgänglig vård. Medicover grundades 1994 och har sitt huvudkontor i Stockholm.

Medicover

* Operational leverage supports beat on adj. EBITDA* Adj. EBITDA revised by +1-0% for '25e-'27e* Unchanged outlook and fair value range of SEK 220-300Continues to show strengthQ3 proved marginally...

* Operational leverage supports beat on adj. EBITDA* Adj. EBITDA revised by +1-0% for '25e-'27e* Unchanged outlook and fair value range of SEK 220-300Continues to show strengthQ3 proved marginally weaker than expected on sales, but operational leverage continued to improve, resulting in a 5%/3% beat on adj. EBITDA vs. ABGSCe/Infront consensus. Sales were EUR 592m (-2% vs. ABGSCe, -2% vs. cons.) with organic sales growth of +12% (ABGSCe +15%). Within HS, growth remained solid, supported by the sport/wellness and ambulatory clinics driving FFS growth in Poland. In India, the company is reducing its exposure to public funding, which weighs on growth near term but is expected to be beneficial longer term. In DS, efficiency programmes, volume growth, and price increases continued to support margin expansion, and management highlighted that the segment has navigated the German reimbursement reform well. Both segments contributed to an overall profitability improvement, with the group adj. EBITDA margin at 17.2% (ABGSCe 16.2%, cons. 16.4%).Estimate changesOverall, we leave our operational assumptions largely intact, revising adj. EBITDA by +1-0% for '25e-'27e. Management highlighted three near-term factors that will temporarily affect margins: 1) the launch of two new hospitals in India, brought forward into Q4 to capture strong momentum, 2) some early indications of a more cautious consumer, and 3) a strike in one Indian state during Q4. Despite these short-term effects, we see no changes to the company’s fundamental outlook, and the long-term growth and margin expansion trajectory remains intact.Fair value range unchanged at SEK 220-300With an unchanged long-term outlook and minor estimate revisions, we leave our fair value range at SEK 220-300. The range is derived from trading multiples of two peer groups, one of healthcare providers in developing markets and one in developed markets, alongside a DCF. It corresponds to a '25e EV/EBITDA of 12x-15x.